市場調查報告書
商品編碼
1401871
2030 年 RNA 定序市場預測:按產品、服務、技術、應用、最終用戶和地區進行的全球分析RNA Sequencing Market Forecasts to 2030 - Global Analysis By Product, Service, Technology, Application, End User and By Geography |
根據 Stratistics MRC 的數據,全球 RNA 定序市場在預測期內將以 21.4% 的複合年成長率成長。
RNA 定序(也稱為 RNA-Seq)是一種基因組方法,用於檢測和定量分析生物樣本中的信使 RNA 分子,可用於研究細胞反應。 RNA 定序利用高通量定序方法的力量來深入了解細胞的轉錄組。此方法對於研究基因表現模式、了解細胞過程、識別生物標記以及探索各種研究領域(包括遺傳學、基因組學、分子生物學和醫學)的疾病機制至關重要。
根據罕見疾病國際組織和 EURORDIS 的數據,罕見疾病目前影響著全球人口的 3.5% 至 5.9%。
精準醫療需求不斷成長
RNA測序能夠在分子層面上全面分析個體的遺傳資訊,在精準醫學中發揮重要作用。 RNA 定序有助於識別影響疾病易感性、疾病進展和治療反應的特定基因突變、基因表現模式和遺傳標記。這種全面的知識可以實現個人化的醫療干預,例如標靶治療和基於個人基因譜的治療。此外,隨著精準醫學的加速發展,RNA 定序解釋複雜遺傳資料的能力變得越來越重要。這將促進 RNA 定序融入臨床照護和研究,推動 RNA 定序市場的成長。
資料分析挑戰
由於資料量龐大、任務複雜,資料分析的複雜性是RNA定序市場的抑制因素。 RNA-seq資料分析需要先進的計算基礎設施、專門的演算法和生物資訊學專業知識來準確解釋基因表現模式。跨平台標準化分析方法以確保結果一致是一項挑戰,並且會影響資料可靠性。缺乏熟練的分析師和不斷發展的工具使這一過程更加複雜。因此,市場需求將受到限制。
生物資訊學創新
生物資訊工具和演算法的進步使得複雜 RNA-seq資料的分析、解釋和視覺化變得更加複雜。這些創新提高了資料準確性,並促進基因表現模式、剪接變異體和非編碼 RNA 的識別,使研究人員能夠獲得有意義的生物學見解。此外,改進的軟體解決方案簡化了資料處理,並使更廣泛的用戶可以進行分析。持續的生物資訊學創新也促進了新分析方法的發展,促進了RNA定序在不同研究領域、臨床診斷和藥物開發中更深入的理解和應用。
資料安全和隱私問題
基因組資料的快速成長引發了對詐欺的存取、濫用和敏感遺傳資訊外洩的擔憂。由於 RNA 定序會產生廣泛的個體遺傳圖譜,因此確保這些資料的機密性和安全處理至關重要。潛在風險包括未經授權的資料存取、資訊盜竊以及共用基因組資訊的道德困境。這些擔憂會破壞社會信任,並可能導致對資料共用和使用的監管限制。
COVID-19 大流行對 RNA 定序市場產生了重大影響。儘管最初遇到供應鏈中斷和實驗室限制等障礙,但對 RNA 定序的需求迅速成長。研究人員加速了基因組研究,以了解病毒、開發疫苗並確定潛在的治療方法。該行業見證了自動化和遠端解決方案的發展,以減少操作困難。此外,此次疫情凸顯了RNA定序在感染疾病、癌症和個人化醫療研究中的重要性,促進了市場應用和解決方案的持續擴展和多樣化。
離子半導體定序領域預計將在預測期內成為最大的領域
據估計,離子半導體序列段所佔佔有率最大。離子半導體定序是一種 DNA 定序技術,依賴 DNA 聚合過程中產生的氫離子的識別。此技術可檢測核苷酸摻入不斷生長的 DNA 鏈時所發生的 pH 值變化。離子半導體定序以其快速處理、經濟實惠和適合特定定序應用而聞名。此外,可以透過測量離子濃度的變化來精確識別 DNA 序列,從而實現 RNA 分析以進行基因表現研究、變異檢測和理解生物過程。
學術和研究機構部門預計在預測期內複合年成長率最高
學術和研究機構部門預計在預測期內將出現良好成長。學術和研究機構包括積極從事科學研究和基因組研究的教育機構、大學和研究機構。這些機構透過進行基礎研究、探索新應用和檢驗調查方法,在推進 RNA 定序技術方面發揮著至關重要的作用。他們將 RNA 定序用於多種目的,包括破解基因表現模式、識別生物標記、了解疾病機制以及開發治療性介入。因此,細分市場成長的需求正在增加。
由於精準醫療的日益普及、政府支持基因組研究的舉措以及學術機構和生物技術公司之間研究合作的激增,亞太地區在預測期內佔據了最大的市場佔有率。測序成本降低、臨床診斷應用增加以及主要市場參與企業的存在等因素正在推動市場成長。在個人化醫療需求不斷成長和生物資訊學進步的推動下,亞太地區 RNA 定序市場有望持續擴張和創新,塑造該地區醫療保健和生物研究的未來。
由於 RNA 定序技術的接受度不斷提高,預計北美在預測期內將出現有益成長。該地區的特點是廣泛的研究活動、雄厚的資金籌措和有利的監管環境。基因組學研究投資的增加、學術機構和行業參與企業之間的合作以及精準醫療的興起等因素正在推動市場成長。藥物研發、診斷和個人化醫療對 RNA 定序的高需求,以及定序技術和資料分析工具的進步,正在推動市場向前發展。
According to Stratistics MRC, the Global RNA Sequencing Market is growing at a CAGR of 21.4% during the forecast period. RNA sequencing, also known as RNA-Seq, is a genomic approach for the detection and quantitative analysis of messenger RNA molecules in a biological sample and is useful for studying cellular responses. RNA sequencing uses the capabilities of high-throughput sequencing methods to provide insight into the transcriptome of a cell. This method is crucial for studying gene expression patterns, understanding cellular processes, identifying biomarkers, and exploring disease mechanisms in various research areas, including genetics, genomics, molecular biology, and medicine.
According to Rare Diseases International, and EURORDIS, rare diseases currently affect at any point in time 3.5% - 5.9% of the worldwide population; 72% are genetic, of which around 70% start in childhood.
Growing demand for precision medicine
RNA sequencing plays a crucial role in precision medicine by enabling comprehensive analysis of an individual's genetic information at the molecular level. Identification of particular genetic variants, patterns of gene expression and genetic markers that impact the susceptibility to disease, its progression, and its response to treatment are rendered easier by it. This comprehensive knowledge makes it possible to implement individualised healthcare interventions, such as targeted therapies and therapies based on a person's genetic profile. Moreover, the capacity of RNA sequencing to interpret complex genetic data has become increasingly essential as precision medicine gains pace. This will encourage the integration of RNA sequencing into clinical care and research, which will fuel market growth for RNA sequencing.
Data analysis challenges
Data analysis complexities pose a restraint in the RNA sequencing market due to the immense data volume and intricacies involved. Analysing RNA sequencing data demands advanced computational infrastructure, specialised algorithms, and bioinformatics expertise to interpret gene expression patterns accurately. Standardising analysis methods across platforms for result consistency is challenging, impacting data reliability. A shortage of skilled analysts and evolving tools further complicate the process. Therefore, it will limit market demand.
Innovation in bioinformatics
Advancements in bioinformatics tools and algorithms enable more sophisticated analysis, interpretation, and visualisation of complex RNA sequencing data. These innovations enhance data accuracy, facilitate the identification of gene expression patterns, splice variants, and non-coding RNAs, and empower researchers to extract meaningful biological insights. Furthermore, improved software solutions streamline data processing, making analysis more accessible to a wider range of users. Continual bioinformatics innovation also drives the development of novel analytical methods, fostering deeper understanding and application of RNA sequencing in diverse research fields, clinical diagnostics, and drug development.
Data security and privacy concerns
The exponential growth in genomic data raises apprehensions about unauthorised access, misuse, and breaches of sensitive genetic information. As RNA sequencing generates extensive personal genetic profiles, ensuring the confidentiality and secure handling of this data becomes paramount. Potential risks include unauthorised data access, identity breaches, and ethical dilemmas related to sharing genomic information. These concerns could erode public trust, resulting in regulatory restrictions on data sharing and utilization.
The COVID-19 pandemic had a significant impact on the RNA sequencing market. Despite the initial hurdles imposed by disrupted supply chains and restricted laboratories, demand for RNA sequencing quickly increased. Researchers accelerated genomic studies to understand the virus, develop vaccines, and identify potential treatments. The industry witnessed an evolution in the direction of automated and remote solutions to lessen operational difficulties. Furthermore, the pandemic underscored the significance of RNA sequencing in the investigation of infectious diseases, cancer, and personalised medicine, hence promoting sustained expansion and variety in the market's applications and solutions.
The Ion Semiconductor Sequencing segment is expected to be the largest during the forecast period
The Ion Semiconductor Sequencing segment is estimated to hold the largest share. Ion semiconductor sequencing is a technique for sequencing DNA that relies on the identification of hydrogen ions generated during DNA polymerization. This method involves detecting changes in pH levels generated as nucleotides are incorporated into a growing DNA strand. Sequencing from Ion Semiconductor is renowned for its quick processing, affordability, and fit for specific sequencing applications. Additionally, it can precisely identify DNA sequences by measuring changes in ion concentrations, making RNA analysis for gene expression research, variant detection, and comprehending biological processes possible.
The Academic and Research Institutes segment is expected to have the highest CAGR during the forecast period
The Academic and Research Institutes segment is anticipated to have lucrative growth during the forecast period. The Academic and Research Institutes comprise educational institutions, universities, and research organisations actively engaged in scientific investigations and genomic studies. These entities play a pivotal role in advancing RNA sequencing technologies by conducting fundamental research, exploring novel applications, and validating sequencing methodologies. They leverage RNA sequencing for diverse purposes, including deciphering gene expression patterns, identifying biomarkers, understanding disease mechanisms, and developing therapeutic interventions. Thus, there is an increasing demand for segment growth.
Asia Pacific commanded the largest market share during the extrapolated period owing to rising adoption of precision medicine, government initiatives supporting genomics research, and a surge in collaborations among academic institutions and biotech firms. Factors like reduced sequencing costs, expanding applications in clinical diagnostics, and the presence of key market players are driving market growth. With growing demand for personalised medicine and advancements in bioinformatics, the Asia-Pacific RNA sequencing market is poised for continuous expansion and innovation, shaping the future of healthcare and biological research in the region.
North America is expected to witness profitable growth over the projection period, owing to the rising acceptance for RNA sequencing techniques. It is characterised by extensive research initiatives, robust funding, and a favourable regulatory landscape. Factors such as increasing investments in genomics research, collaborations between academic institutions and industry players, and the prominence of precision medicine drive market growth. The high demand for RNA sequencing in drug discovery, diagnostics, and personalised medicine, along with advancements in sequencing techniques and data analysis tools, propels the market forward.
Some of the key players in the RNA Sequencing Market include Thermo Fischer Scientific, Illumina, Tecan Genomics Inc., Agilent Technologies Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., GE Healthcare, Bio-Rad Laboratories Inc., Eurofins Scientific, Sigma Aldrich, Admera Health, CD Genomics, Biogazelle, Creative Biogene, LC Sciences, IGA Technology , Lexogen, Otogenetics, Novogene, Yaazh Xenomic and Oxford Nanopore Technologies.
In August 2023, Thermo Fisher Scientific, the world leader in serving science, announced the launch of a new chromosomal microarray designed to improve cytogenetic research lab productivity, efficiency and profitability with an industry-leading two-day turnaround time.
In May 2023, Thermo Fisher Scientific, the world leader in serving science, expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune conditions to rare genetic disorders.
In March 2021, Thermo Fisher Scientific Inc., declared the introduction of the Thermo Scientific Aerosol Sense Sampler, a novel surveillance solution planned to transfer speedy and greatly trustworthy insight into the existence of in-air pathogens, inclusive of SARS-CoV-2. Individual testing will persist in being essential in the COVID-19 pandemic response owing to its ability to allow and apprise clinical diagnoses, patient triage, and treatment decisions.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.